Education
About Us
Working with TipRanks
Follow Us
BioMarin Pharmaceutical (BMRN)
NASDAQ:BMRN
Earnings Data
Report Date
Feb 25, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
0.78Last Year’s EPS
0.64Same Quarter Last Year
Strong Buy
Based on 22 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call highlighted BioMarin's strong revenue growth, particularly with VOXZOGO and enzyme therapies, alongside a solid cash position and operational efficiency. However, challenges included a significant IPR&D charge, the decision to divest ROCTAVIAN, and enzyme therapy revenue fluctuations. While there are notable achievements, the presence of significant lowlights balances the overall sentiment.Company Guidance
Revenue Growth and Financial Performance
BioMarin achieved an 11% increase in total revenue year-over-year, driven by strong performance in enzyme therapies and skeletal conditions. The company raised its full-year total revenue guidance to a range of $3.15 billion to $3.25 billion.
VOXZOGO's Strong Performance
VOXZOGO revenue increased by 24% year-to-date compared to 2024, with expectations for full-year 2025 revenue between $900 million and $935 million, representing a 25% growth at the midpoint of the guidance range.
Cash and Investments
BioMarin's cash and investments balance reached approximately $2 billion by the end of the third quarter.
Operational Efficiency and Profitability
Despite the IPR&D charge, BioMarin achieved increased GAAP and non-GAAP diluted earnings per share year-to-date, alongside robust operating cash flow of $369 million in the third quarter and $728 million year-to-date.
BMRN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BMRN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Oct 27, 2025 | $52.67 | $53.49 | +1.56% |
Aug 04, 2025 | $60.31 | $61.93 | +2.69% |
May 01, 2025 | $62.71 | $62.03 | -1.08% |
Feb 19, 2025 | $65.61 | $68.73 | +4.76% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does BioMarin Pharmaceutical (BMRN) report earnings?
BioMarin Pharmaceutical (BMRN) is schdueled to report earning on Feb 25, 2026, After Close (Confirmed).
What is BioMarin Pharmaceutical (BMRN) earnings time?
BioMarin Pharmaceutical (BMRN) earnings time is at Feb 25, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BMRN EPS forecast?
BMRN EPS forecast for the fiscal quarter 2025 (Q4) is 0.78.
